Swissmedic said the United States pharmaceutical company Pfizer submitted an application for the authorisation of a vaccine which is based on the mRNA technology last week.
The agency added it is fast-tracking all applications connected with the Covid-19 pandemic, assigning extra staff to this task so that content checks and, in particular, user safety are not compromised.
The criteria for reviewing safety, efficacy and quality remain unchanged, according to Claus Bolte, head of Swissmedic’s authorisation division.
“The data packages for the vaccine candidates will be reviewed just as comprehensively, but faster. As a result, we can shorten the waiting times between the development stages during the review,” Bolte said in a statementExternal link published on Monday.
Two weeks ago, the Swiss authorities started assessing an application for a vaccine developed by the British-Swedish company AstraZeneca and Oxford University.
Switzerland has also signed a deal with US biotech firm Moderna to secure early access to 4.5 million doses of its Covid-19 vaccine.
Popular Stories
More
Culture
Wealth is not all: how gentrification in Zurich has led to housing shortage
Swiss invention: 90-year anniversary of first T-bar ski lift
This content was published on
On Monday it will be 90 years since the world’s first T-bar ski lift went into service in Davos. This Swiss invention was an instant success.
Iran summons Swiss ambassador over US and Italy arrests
This content was published on
Iran has summoned the Swiss ambassador, who represents US interests, to protest against the arrest in the US and Italy of two Iranians.
Swisscom receives greenlight for acquisition of Vodafone Italia
This content was published on
The takeover of Vodafone Italia by Swisscom is nearing completion. All relevant authorities have now approved the €8 billion (CHF7.45 billion) deal.
Novo Nordisk stock market plunge drags down Swiss device maker Ypsomed
This content was published on
The Danish pharmaceutical giant, Novo Nordisk, faced setbacks on Friday that weighed on the share price of Swiss injection device manufacturer Ypsomed.
Swiss press react to EU deal with mix of euphoria and scepticism
This content was published on
Swiss media reaction to the agreement between Switzerland and the EU varies widely. Some are celebrating, while others worry about what is to come.
Swiss Solidarity donations to tackle child abuse top CHF4 million
This content was published on
Swiss Solidarity, the humanitarian arm of the Swiss Broadcasting Corporation (SBC), has raised over CHF4 million ($4.3 million) to tackle child abuse.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Covid cure further away than hoped, says Novartis chief
This content was published on
Swiss pharmaceutical firm Novartis has rowed back on earlier predictions that a drug to combat coronavirus could be on the horizon.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.